Close Menu

BMS

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Bristol Myers-Squibb and Saladax Biomedical today expanded an agreement covering companion diagnostics to include Johnson & Johnson's Ortho-Clinical Diagnostics.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – GNS Healthcare today announced a deal to use clinical and molecular information from Bristol-Myers Squibb aimed at immuno-inflammation.

Advanced sequencing technologies are great for discovery, but not ready to be incorporated into Qiagen's commercial companion diagnostics portfolio, according to CEO Peer Schatz.

The deal marks the first pharma alliance for Evotec since it acquired Kinaxo in mid-April in a deal worth up to $23 million.

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

By exploring a treatment strategy that involves Roche/Plexxikon's investigational pharmacogenomically targeted drug vemurafenib and Bristol-Myers Squibb's newly approved melanoma treatment Yervoy, two large drug developers are hoping to further improve outcomes for a genomically defined patient population.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

Pages

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.